Myeloma Euronet

الشبكة الاوروبية لمجموعة مرضى المايلوما

هذه الصفحة متوفرة باللغة الانكليزية ، الترجمة العربية ستتوفر قريباً

Supporting Members

Patient organization-commercial company partnerships are sometimes viewed with scepticism by decision-makers and the general public. Some believe that pharmaceutical companies coerce patient organizations into conforming to their marketing agenda. In order to protect the Network's reputation and demonstrate that Myeloma Euronet does not conform to commercial agendas, the Network has adopted a detailed Funding Policy.

Supporting Members

2008

  • Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
  • Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
  • Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
  • Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
  • Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.

2007

  • Myeloma Euronet is supported by an unrestricted grant from Amgen Inc.
  • Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
  • Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
  • Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
  • Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
  • Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
  • Myeloma Euronet is supported by an unrestricted grant from Roche.
  • Myeloma Euronet is supported by an unrestricted grant from The Steel Charitable Trust.

2006

  • The Portuguese translation of this Web site was made possible through a restricted grant from Amgen Inc..
  • Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
  • Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
  • Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
  • Myeloma Euronet is supported by an unrestricted grant from Roche.

2005

  • Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag, is the founding sponsor of Myeloma Euronet.
  • Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
  • Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.


 

الدكتور علي المظفر/ استاذ امراض الدم/ كلية الطب جامعة بغداد